In the wake of the first practical application of Japan’s cost effectiveness assessment (CEA) system to innovative drugs from some of its member companies, the Japanese arm of the European Federation of Pharmaceutical Industries and Associations (EFPIA) has put forward a number of changes it believes would improve the scheme.
The Central Social Insurance Medical Council (Chuikyo), an advisory body on drug pricing to the Ministry of Health, Labour and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?